Green Cross WellBeing Corporation (234690.KQ) Stock

234690.KQ logo

Green Cross WellBeing Corporation

234690.KQSouth Korea
Healthcare

Company profile

Green Cross WellBeing reported revenue of 164.68 billion KRW for fiscal year 2025, up 23.1% from fiscal year 2024, and net income of 10.01 billion KRW. That is a net profit margin of 6.1% for fiscal year 2025. In Q1 2026 (the quarter ended March 31, 2026) revenue was 49.13 billion KRW, up 41.3% from a year before. Its largest business segment, Prescription Drugs, brought in 80% of segment revenue in fiscal year 2025. In Q1 2026 it reported a net loss of 3.05 billion KRW, against net income of 5.10 billion KRW a year earlier. Our analysis of its filings shows revenue growing from 120.53 billion KRW in fiscal year 2023 to 164.68 billion KRW in fiscal year 2025, 16.9% a year on average. Green Cross WellBeing reports about 335 full-time employees.

What stands out

  • Revenue and net income in fiscal year 2025 were the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2025.

About Green Cross WellBeing Corporation

GC WellBeing Corporation provides personalized nutrition injections in South Korea. The company offers health supplements and food; prescription drugs; and aesthetics, as well as nutritional injections, including vitamins and antioxidants. The company was formerly known as GREEN CROSS WellBeing Corporation and changed its name to GC WellBeing Corporation in April 2026. The company was founded in 2004 and is headquartered in Seoul, South Korea.

Largest shareholders

  • Gc Corp.34.06%
  • Jbp Korea11.38%
  • Eun-Cheol Huh1.67 %1.67%
  • Yong-Jun Huh1.67 %1.67%
  • Human Life Well-Being No 1 Private Equity Investment Partnersh1.18%

Share of the company, as of September 25, 2026

Leadership

  • SangHyun Kim — CEO & Director, 60

How much revenue does Green Cross WellBeing make?

Green Cross WellBeing reported 164.68 billion KRW in revenue for fiscal year 2025, up 23.1% from 133.80 billion KRW in fiscal year 2024. In Q1 2026 revenue was 49.13 billion KRW.

What is Green Cross WellBeing's largest business segment?

Prescription Drugs, with 134.21 billion KRW or 80% of segment revenue in fiscal year 2025. Next: Health Functional Food (20%).

What companies are similar to Green Cross WellBeing?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include DAE HWA Pharmaceutical Co., Ltd. (067080.KQ), Daewon Pharmaceutical Co., Ltd. (003220.KS), Kangstem Biotech Co., Ltd. (217730.KQ), Ilsung Is Co., Ltd. (003120.KS).

How has Green Cross WellBeing's revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, 90.97 billion KRW; FY2022, 109.73 billion KRW; FY2023, 120.53 billion KRW; FY2024, 133.80 billion KRW; FY2025, 164.68 billion KRW.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees335
HeadquartersSeoul, South Korea
ExchangeKOSDAQ
TimezoneAsia/Seoul (KST)

Contact & Links

Address
Park One Tower, Seoul
Phone
82 1 577 5560
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Green Cross WellBeing Corporation (234690.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/234690.KQ

LinkedInLinkedInXXYouTubeYouTube